Imiphumo ye-Cardiovascular effects ihluke phakathi kweCelebrex, iVixx kunye ne-NSAID ezindala.
Eli nqaku liyingxenye ye- Arthritis Archives.
Inqaku lomhleli: Ngomhlaka 09/30/2004, uMerck umenzi we-Vioxx, wakhupha umhlaba wonke, ukhubaza ukuthengisa kweziyobisi. Ngo-04/07/2005, emva kokuhlolisiswa kweklasi yezilwanyana ze-arthritis ezibizwa ngokuba yi-NSAID kunye ne-COX-2 inhibitors, i-FDA yamemezela izenzo zokulawula ezicwangcisiweyo.
Idateline: Ngomhla wama-29, 2004
Isifundo seCanada sibonisa iCelebrex Ingaba yi-Safest Anti-Inflammatory drug kubantu basebekhulile
Abantu abaneempawu zesifo se-arthritis bavame ukushicilelwa esinye sezidakamizwa ezingabalulekanga, ezingenayo i-nonsteroidal anti-inflammatory (NSAIDs) okanye enye yeqela elitsha le-NSAIDS elaziwa njenge-cyclo-oxygenase-2 inhibitors ( COX-2 inhibitors ekhethiweyo ).
I-NSAID ezingakhethi ziye zadibana nomngcipheko wokunyuka kwentliziyo. Ingaphantsi iyaziwa okanye iqukunjelwe ngemiphumo ye-cardiovascular ye-COX-2 inhibitors ekhethiweyo.
I-Lancet (2004; 363: 1751-56) ibonakalise iziphumo zophando lwaseCanada ezibandakanya abantu abangaphezu kwe-130 000 abadala. U-Muhammad Mamdani ovela kwiZiko leeNzululwazi zeSiklinikhi, eToronto, eKhanada, kunye nabalingani bakhe bahlalutya ngokutsha ingozi yokubakholiswa esibhedlele ngenxa yokungaphumeleli kwentliziyo ngeenxa zonke:
- Abantu abayi-14 500 basebenzisa i-COX-2 inhibitor iVoxx (rofecoxib)
- Abantu abayi-19,000 basebenzisa i-COX-2 inhibitor Celebrex (celecoxib)
- Abantu abangama-5 400 basebenzisa ii-NSAID ezingakhethi
- Abantu abayi-100,000 abangasebenzisi naliphi i-NSAID ekhonza njengeqela lolawulo
Iziphumo zophando
Xa kuthelekiswa neqela lolawulo labasebenzisi abangewona i-NSAID, iziphumo zi:
- Abantu basebenzisa iVixx babenomngcipheko we-80% wokwandisa esibhedlele ngenxa yokungaphumeleli kwentliziyo.
- Abantu abasebenzisa ii-NSAID ezingabonayo babenomngcipheko we-40% owongeziweyo wokungenwa kwintliziyo ye-congestive.
- Abantu basebenzisa iCelebrex babenomlinganiselo ofanayo wokufakwa kwesibhedlele ngenxa yokungaphumeleli kwentliziyo njengabantu abangakaze basebenzise ii-NSAID.
Ukwahlukana phakathi kwe-NSAIDS engakhethiyo kunye ne-COX-2 inhibitors nganye ekuvunyelwene ngayo ukungenwa kwintliziyo ye-congestive kuyabonakala ibonisa ukuba kufuneka iimvavanyo ezinkulu, ezilandeleleneyo, ezilawulwayo ukuba ziqhubele phambili ukufundisisa.
Izixhobo ezinxulumene nazo
- Celebrex (Celecoxib)
- Vioxx (Rofecoxib)
- I-COX-2 Inhibitors Ekhethiweyo
- Olongezelelweyo NgeeNSAID
- IArthritis Medication
Umthombo: I-COX-2 Inhibitor ingaba yi-Safest Anti-Inflammatory Drug kubantu abadala, i-Lancet Issue 29 Meyi 2004
Ukupapashwa kokuqala: 05/29/2004